Lumicitabine - Alios BioPharma/Janssen

Drug Profile

Lumicitabine - Alios BioPharma/Janssen

Alternative Names: AL 8176; ALS 008176; ALS-8176; JNJ-1575; JNJ-64041575

Latest Information Update: 08 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Janssen Research & Development
  • Class Antivirals; Furans; Nucleosides; Pyrimidines
  • Mechanism of Action RNA replicase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections
  • Preclinical Metapneumovirus infections; Parainfluenza virus infections

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In infants) in Australia (PO, Suspension)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In infants) in Canada (PO, Suspension)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In infants) in Chile (PO, Suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top